Development of Clinical Pharmacy Standards in Oncology - PowerPoint PPT Presentation

1 / 33
About This Presentation
Title:

Development of Clinical Pharmacy Standards in Oncology

Description:

Development of Clinical Pharmacy Standards in Oncology Joanne Robinson Senior Pharmacist Oncology NHS Forth Valley Member of Scottish Oncology Pharmacy Practice Group – PowerPoint PPT presentation

Number of Views:387
Avg rating:3.0/5.0
Slides: 34
Provided by: Regis240
Category:

less

Transcript and Presenter's Notes

Title: Development of Clinical Pharmacy Standards in Oncology


1
Development of Clinical Pharmacy Standards in
Oncology
  • Joanne Robinson
  • Senior Pharmacist Oncology
  • NHS Forth Valley
  • Member of Scottish Oncology Pharmacy Practice
    Group

2
Spot the Difference
Job title Cancer Care Pharmacist
Job title Cancer Care Pharmacist
3
Spot the Difference
Job title Cancer Care Pharmacist Based within
aseptic services Clinical check of prescription
involves BSA dose check Appropriate
administration Appropriate supportive care
Job title Cancer Care Pharmacist Based on
ward/clinic Clinical check of prescription
involves Check of diagnosis and staging BSA
dose check FBC, LFT UE check Appropriate
supportive care
4
Content
  • Development of Scottish SOP for pharmaceutical
    care planning
  • Development of ASTCP capacity plan for cancer
  • Update to clinical capacity plan
  • Development of clinical quality standards in
    oncology

5
Scottish Care Planning Standards
  • Developed in 2001
  • Aim to standardise clinical pharmacy practice in
    chemotherapy across Scotland
  • GUIDELINES FOR THE COMPLETION OF PHARMACEUTICAL
    CARE PLAN FOR CANCER PATIENTS RECEIVING
    CHEMOTHERAPY
  • STANDARDISED PHARMACEUTICAL CARE PLAN
    DOCUMENTATION

6
Elements of PCP
  • All patients receiving chemotherapy IV or oral
  • PMH
  • Previous treatment for cancer
  • Current medication
  • Height, Weight, BSA
  • Chemotherapy eligibility
  • Chemotherapy appropriateness
  • Drugs/doses
  • Administration
  • Immunosuppressants
  • Monitoring Issues
  • Individual care issues

7
(No Transcript)
8
(No Transcript)
9
Care Planning in Practice
  • Care plan in original format used in majority of
    units/centres
  • Some units/centres have kept same elements but
    adapted for local use

10
Care Planning in Practice
  • Advantages
  • Standardises practice
  • Allows us to define what is meant by clinical
    verification
  • Disadvantages
  • Documentation may duplicate effort
  • Very few like the ticks and crosses

11
Application of Capacity Plan
  • Cancer in Scotland Action for Change published
    in 2001
  • In excess of 50million investment promised
  • ASTCP took unified approach to secure funding for
    pharmacy cancer services
  • Scottish capacity plan for pharmacy services to
    cancer patients was developed
  • Scotland-wide bid submitted for cancer pharmacy
    staffing

12
Success!
  • gt 1 million secured for pharmacy staff
  • gt 1 million secured for pharmacy equipment

13
What was this based on?
  • Safe staffing levels
  • Aseptic dispensing based on items
  • Dispensing services based on items
  • Clinical pharmacy services based on patient
    numbers
  • 1 pharmacist 20 outpatients per day
  • 1 pharmacist 30 inpatients per day
  • Based on consensus of opinion which was
    benchmarked against current practice.

14
Limitations of Model
  • Model did not take into account complexity of
    workload
  • Some patient groups require more intensive input
    eg BMT
  • Some patients require more patient education eg
    Capecitabine

15
Update to Capacity Plan - 2007
  • Scottish Oncology Pharmacy Practice (SOPPG) and
    Scottish Aseptic Services Specialist Interest
    Group (ASSIG) tasked with updating capacity plan
  • Aseptic capacity plan was updated taking into
    complexity of preparation and dispensing of dose
    banded products
  • Approved by Directors of Pharmacy Group 2008

16
Update to Clinical Capacity Plan
  • Incorporate complexity of workload
  • Inpatients v outpatients
  • Oncology v haematology
  • First step was to survey opinion of cancer
    pharmacists in 19 hospitals across all 3 cancer
    networks, cancer centres and cancer units

17
Update to Clinical Capacity Plan
  • Next step test assumptions
  • Pharmacists asked to measure the actual time
    taken for outpatients and inpatients
  • 9 centres participated
  • New outpatients 58
  • Return outpatients 241
  • New inpatients 40
  • Return inpatients 88
  • Non-chemo inpatients 102

18
New Model
  • No difference between oncology and haematology in
    terms of timings
  • Still needed different models for outpatients and
    inpatients
  • Need to differentiate between routine and complex
    inpatients

19
Model for Outpatients
  • Timings
  • Chemotherapy care planning cycle 1
  • 16 minutes
  • Chemotherapy care planning cycle 2 onwards
  • 12 minutes
  • Patient education
  • Simple 6 minutes
  • Intermediate 12 minutes
  • Complex 18 minutes

20
Spreadsheets
  • Devised to work out
  • How many pharmacists required to care plan a
    certain number of patients in a certain time
    period
  • or
  • The total number of pharmacist hours required to
    care plan the total number of patients
  • Takes into account a 15 efficiency factor to
    account for peaks in workload
  • Allows for liaison time eg phoning, faxing,
    communication etc

21
(No Transcript)
22
Model for Inpatients
  • Timings
  • New admission for chemotherapy cycle 1
  • 20 minutes
  • New admission for chemotherapy from cycle 2
  • 15 minutes
  • New admission no chemo
  • 11 minutes
  • Patients from day 2
  • 6 minutes
  • Discharge Planning
  • 10 minutes
  • Patient Education
  • 6, 12, 18 minutes

23
(No Transcript)
24
Complex Inpatients
  • Timings
  • New admission
  • 25 minutes
  • Subsequent days
  • 15 minutes
  • Rest as per standard inpatients

25
Next steps
  • Model was endorsed by the Scottish Directors of
    Pharmacy Group
  • Timings to be incorporated into C-PORT pilot
    sites to further validate
  • Agreement to share model UK wide and work
    collaboratively with BOPA to develop UK quality
    standards for cancer pharmacists

26
Applicability to UK
  • Cancer Action Team
  • All chemotherapy prescriptions should be checked
    by an oncology pharmacist, who has undergone
    specialist training, demonstrated their
    appropriate competence and is locally authorised/
    accredited for the task.
  • NCEPOD report (2008)
  • Pharmacists should sign the SACT prescription to
    indicate that it has been verified and validated
    for the intended patient and that all the safety
    checks have been undertaken.
  • What does this signature mean?
  • May mean different things to different people

27
Standardising Clinical Verification
  • BOPA to consult on the minimum requirements for a
    pharmacist verification check
  • Acknowledges there are differences in practice
    across the UK and therefore there needs to be
    flexibility in working practice
  • Some elements may not require to be personally
    undertaken by the pharmacist as long as there is
    a documented system in place to ensure that these
    checks are undertaken

28
Elements of Verification 1
  • Check Patients details are correct on
    prescription
  • Check prescribers details
  • Check regimen protocol is appropriate for
    patients diagnosis, medical history and
    chemotherapy history
  • Check regimen is the intended regimen
  • Complete pharmaceutical care plans/ patient
    record
  • Check there are no known drug interactions or
    conflicts with patient allergies
  • Check body surface area (BSA) is correctly
    calculated, taking into account most recent
    weight.

29
Elements of Verification 2
  • Check dose calculations and dose units are
    appropriate according to BSA
  • Check reason for any dose reduction(s)
  • Check method of administration is appropriate
  • Check laboratory values, FBC, UE and LFTs
  • Check doses are appropriate with respect to renal
    and hepatic function and any experienced
    toxicities
  • Check other essential laboratory tests have been
    undertaken
  • Check supportive care prescribed is appropriate
    for the patient

30
Next Steps in Scotland
  • Standard pharmaceutical care plan will be updated

31
Next Steps - BOPA
  • Consultation on Verification standards
  • Produce supporting toolkit/ guidance that gives
    details to inform SOPs
  • Work with Scottish Cancer Pharmacy Group to
    further validate capacity plan
  • Generic care plan made available for local use or
    adaptation

32
Advantages
  • Ensure safe provision of chemotherapy
  • Standardisation of practice
  • Tool for improving access to information for
    pharmacists
  • Standards of practice allow capacity planning to
    be undertaken on larger scale
  • More credibility due to national system
  • Incorporate into future systems eg CPORT

33
Spot the Difference
Job title Cancer Care Pharmacist Based within
aseptic services Clinical check of prescription
involves BOPA approved verification steps
Job title Cancer Care Pharmacist Based on
ward/clinic Clinical check of prescription
involves BOPA approved verification steps
No Difference!
Write a Comment
User Comments (0)
About PowerShow.com